Detalhe da pesquisa
1.
Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease.
Ann Neurol
; 95(2): 274-287, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37837382
2.
Donanemab in Early Alzheimer's Disease.
N Engl J Med
; 384(18): 1691-1704, 2021 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33720637
3.
The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB).
Alzheimers Dement
; 20(1): 695-708, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37774088
4.
Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-ß monoclonal antibodies in dominantly inherited Alzheimer's disease.
Eur J Nucl Med Mol Imaging
; 50(9): 2669-2682, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37017737
5.
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
JAMA
; 330(6): 512-527, 2023 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37459141
6.
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
Brain
; 142(6): 1723-1735, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31009046
7.
Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
Brain
; 139(Pt 5): 1539-50, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26936940
8.
Initial study of radiological and clinical efficacy radioembolization using 188Re-human serum albumin (HSA) microspheres in patients with progressive, unresectable primary or secondary liver cancers.
Med Sci Monit
; 20: 1353-62, 2014 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-25086245
9.
Personalized image-based radiation dosimetry for routine clinical use in peptide receptor radionuclide therapy: pretherapy experience.
Recent Results Cancer Res
; 194: 497-517, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-22918779
10.
Preclinical PET Imaging and Toxicity Study of a 68Ga-Functionalized Polymeric Cardiac Blood Pool Agent.
Pharmaceutics
; 15(3)2023 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36986628
11.
Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.
Clin Pharmacol Ther
; 113(6): 1258-1267, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36805552
12.
Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease.
Alzheimers Dement (N Y)
; 9(2): e12404, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37388759
13.
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease.
Alzheimers Dement (N Y)
; 9(3): e12415, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37600216
14.
Phylogenetic Characterization of Rabies Virus Field Isolates Collected from Animals in European Russian Regions in 2009-2022.
Microorganisms
; 11(10)2023 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37894184
15.
Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical Trial.
J Alzheimers Dis Rep
; 7(1): 1015-1024, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37849628
16.
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels.
JAMA Neurol
; 80(12): 1295-1306, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37930695
17.
Novel CYP1B1-RMDN2 Alzheimer's disease locus identified by genome-wide association analysis of cerebral tau deposition on PET.
medRxiv
; 2023 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36993271
18.
Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia.
Alzheimers Dement (N Y)
; 8(1): e12313, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35783453
19.
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
JAMA Neurol
; 79(10): 1015-1024, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36094645
20.
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.
JAMA Neurol
; 79(12): 1250-1259, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36251300